This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
coronavirus disease | 94 |
acute respiratory | 79 |
public health | 71 |
novel coronavirus | 68 |
respiratory syndrome | 58 |
severe acute | 49 |
doc id | 45 |
trop med | 45 |
cord uid | 45 |
hyg doi | 45 |
med hyg | 45 |
respiratory distress | 41 |
healthcare workers | 41 |
dengue virus | 41 |
face masks | 41 |
control group | 39 |
school closure | 37 |
united states | 36 |
malaria cases | 30 |
systematic review | 30 |
infectious diseases | 30 |
income countries | 29 |
education module | 29 |
pulmonary embolism | 29 |
imported cases | 28 |
severe covid | 28 |
article distributed | 27 |
original author | 27 |
permits unrestricted | 27 |
commons attribution | 27 |
unrestricted use | 27 |
access article | 27 |
creative commons | 27 |
intensive care | 26 |
distress syndrome | 26 |
infectious disease | 25 |
spontaneous pneumothorax | 25 |
developing countries | 25 |
guangdong province | 24 |
case report | 24 |
virus infections | 23 |
syndrome coronavirus | 23 |
risk factors | 23 |
clinical trials | 22 |
unmc nm | 22 |
hypoxemic pneumonia | 22 |
face mask | 22 |
disease control | 21 |
falsified medicines | 21 |
hospitalized patients | 20 |
cohort study | 20 |
supply chain | 20 |
severe disease | 20 |
computed tomography | 19 |
nervous system | 19 |
zhejiang province | 19 |
public holiday | 19 |
clinical characteristics | 19 |
medical products | 19 |
risk infection | 18 |
middle east | 18 |
east respiratory | 18 |
medical masks | 18 |
weight loss | 17 |
mouth disease | 17 |
control measures | 16 |
world health | 16 |
artemisia annua | 16 |
clinical symptoms | 16 |
factors associated | 16 |
recent years | 16 |
contact tracing | 16 |
respiratory infections | 16 |
viral load | 16 |
increased risk | 15 |
infected mice | 15 |
per country | 15 |
physical distancing | 15 |
health organization | 15 |
disease severity | 15 |
denv igm | 15 |
hong kong | 14 |
genotype i | 14 |
reproduction number | 14 |
respiratory symptoms | 14 |
ill patients | 14 |
denv infection | 14 |
tested positive | 14 |
cell count | 14 |
disseminated strongyloidiasis | 14 |
respiratory tract | 14 |
first case | 14 |
confirmed covid | 14 |
global health | 13 |
intervention group | 13 |
oral transmission | 13 |
education level | 13 |
lung us | 13 |
symptom onset | 13 |
community transmission | 13 |
clinical trial | 13 |
quality medicines | 13 |
travel restrictions | 13 |
combination therapy | 13 |
respiratory illness | 13 |
severe pneumonia | 13 |
lung ultrasound | 13 |
high risk | 13 |
mechanical ventilation | 13 |
cytokine storm | 13 |
healthcare system | 13 |
critically ill | 12 |
protective equipment | 12 |
dengue fever | 12 |
two cases | 12 |
saharan africa | 12 |
positive rt | 12 |
distancing measures | 12 |
epidemiological characteristics | 12 |
hiv infection | 12 |
respiratory failure | 12 |
controlled trial | 12 |
phylogenetic analysis | 12 |
sore throat | 12 |
risk factor | 12 |
chest ct | 12 |
hiv aids | 12 |
two groups | 12 |
regarding covid | 12 |
returning travelers | 12 |
diabetes mellitus | 11 |
falsified products | 11 |
ongoing pandemic | 11 |
clinical features | 11 |
health services | 11 |
care unit | 11 |
hypoxemic patients | 11 |
viral rna | 11 |
waived due | 11 |
observational study | 11 |
molecular evolution | 11 |
observational cohort | 11 |
pleural thickening | 11 |
confirmed cases | 11 |
pneumonia cases | 11 |
ebola virus | 11 |
ethics committee | 11 |
old man | 11 |
combination therapies | 11 |
publication charges | 11 |
endemic areas | 11 |
secondary school | 11 |
infected individuals | 11 |
central nervous | 11 |
personal protective | 11 |
respiratory viruses | 11 |
spontaneous pneumomediastinum | 11 |
pleural line | 11 |
mask containers | 11 |
reactive protein | 10 |
viral shedding | 10 |
poor quality | 10 |
converting enzyme | 10 |
social media | 10 |
chain reaction | 10 |
viral pneumonia | 10 |
upper respiratory | 10 |
informed consent | 10 |
influenzae non | 10 |
tissue reservoirs | 10 |
significant difference | 10 |
polymerase chain | 10 |
mortality rate | 10 |
lung disease | 10 |
infected patients | 10 |
social distancing | 10 |
large number | 10 |
paralytic ileus | 10 |
pneumonia due | 10 |
ct scan | 10 |
health systems | 10 |
influenzae type | 10 |
hcq group | 10 |
ng ml | 9 |
case definition | 9 |
school students | 9 |
quality drugs | 9 |
school vacations | 9 |
lessons learned | 9 |
viral infections | 9 |
critical care | 9 |
large bowel | 9 |
african countries | 9 |
immune responses | 9 |
deep vein | 9 |
streptococcus pneumoniae | 9 |
standard care | 9 |
inflammatory response | 9 |
sars coronavirus | 9 |
infection prevention | 9 |
incubation period | 9 |
extrapulmonary tissues | 9 |
hace mice | 9 |
health workers | 9 |
ray showed | 9 |
vein thrombosis | 9 |
reverse transcription | 9 |
clinical course | 9 |
dengue viruses | 9 |
logistic regression | 9 |
respiratory pathogens | 9 |
pulse oximetry | 9 |
health care | 9 |
virus disease | 9 |
immune response | 9 |
health system | 8 |
subcutaneous emphysema | 8 |
neglected tropical | 8 |
factor analysis | 8 |
five patients | 8 |
patients may | 8 |
ili cases | 8 |
epidemiological data | 8 |
million people | 8 |
imported malaria | 8 |
blood pcr | 8 |
good quality | 8 |
respiratory disease | 8 |
potential role | 8 |
drug administration | 8 |
reunion island | 8 |
asymptomatic patients | 8 |
case reports | 8 |
supplemental table | 8 |
falsified medical | 8 |
oxygen therapy | 8 |
coronavirus pneumonia | 8 |
line abnormalities | 8 |
supply chains | 8 |
infection control | 8 |
higher risk | 8 |
lopinavir ritonavir | 8 |
oxygen saturation | 8 |
hfmd transmission | 8 |
regulatory agencies | 8 |
first covid | 8 |
microbiological agents | 8 |
three brothers | 8 |
study population | 8 |
pcr results | 8 |
public holidays | 8 |
current pandemic | 8 |
respiratory samples | 8 |
genotypes i | 7 |
host immune | 7 |
positive effect | 7 |
animal models | 7 |
close contact | 7 |
severe illness | 7 |
underlying disease | 7 |
tropical diseases | 7 |
platform trials | 7 |
transmission dynamics | 7 |
median age | 7 |
among healthcare | 7 |
conspiracy theories | 7 |
gastrointestinal symptoms | 7 |
high incidence | 7 |
reverse transcriptase | 7 |
healthcare systems | 7 |
uri cases | 7 |
general public | 7 |
blood cell | 7 |
randomized clinical | 7 |
statistical analysis | 7 |
virus infection | 7 |
infected persons | 7 |
respiratory infection | 7 |
immune system | 7 |
analysis showed | 7 |
falciparum malaria | 7 |
time point | 7 |
emerging infections | 7 |
locally transmitted | 7 |
aged years | 7 |
close contacts | 7 |
dengue outbreak | 7 |
case series | 7 |
attribution license | 7 |
human coronavirus | 7 |
hfmd cases | 7 |
randomized controlled | 7 |
neurological manifestations | 7 |
severe cases | 7 |
four patients | 7 |
hiv viral | 7 |
literature review | 7 |
transmitted cases | 7 |
united kingdom | 7 |
safely managed | 7 |
hospital beds | 7 |
stepwise approach | 7 |
fatality rate | 7 |
cases contracted | 7 |
physical examination | 7 |
cumulative number | 7 |
democratic republic | 7 |
bowel dilatation | 7 |
care ultrasound | 7 |
adverse events | 7 |
global burden | 7 |
abnormal cxr | 7 |
sample size | 7 |
chest computed | 7 |
clinical improvement | 7 |
hand hygiene | 7 |
high levels | 7 |
isolation care | 7 |
preventive measures | 7 |
hospitalized children | 6 |
clinical benefit | 6 |
neurological diseases | 6 |
south korea | 6 |
pleural effusion | 6 |
hospital day | 6 |
prone positioning | 6 |
may also | 6 |
lung injury | 6 |
bacterial species | 6 |
hospital mortality | 6 |
managed sanitation | 6 |
mild symptoms | 6 |
mg dl | 6 |
respiratory rate | 6 |
clinical signs | 6 |
nasopharyngeal swab | 6 |
np swab | 6 |
many countries | 6 |
neighboring countries | 6 |
life sciences | 6 |
case fatality | 6 |
fecal matter | 6 |
ethical approval | 6 |
military populations | 6 |
financial support | 6 |
multiplex assay | 6 |
chest indrawing | 6 |
acute kidney | 6 |
type i | 6 |
tropical medicine | 6 |
proposed expenditure | 6 |
twice daily | 6 |
closely related | 6 |
credible intervals | 6 |
health measures | 6 |
poor prognosis | 6 |
cardiovascular diseases | 6 |
renal failure | 6 |
glass opacities | 6 |
varying reproduction | 6 |
virus type | 6 |
constituent studies | 6 |
per day | 6 |
household water | 6 |
viral replication | 6 |
tb treatment | 6 |
significant differences | 6 |
within days | 6 |
patients admitted | 6 |
mortality rates | 6 |
studies reported | 6 |
bacterial pneumonia | 6 |
drug quality | 6 |
median time | 6 |
medical staff | 6 |
limited settings | 6 |
relatively high | 6 |
per person | 6 |
significantly associated | 6 |
retrospective study | 6 |
molecular evolutionary | 6 |
asymptomatic cases | 6 |
epub ahead | 6 |
gamma globulin | 6 |
school closures | 6 |
active learning | 6 |
confirmed case | 6 |
coronavirus infection | 6 |
lower respiratory | 6 |
among children | 6 |
case management | 6 |
disease transmission | 6 |
preuniversity education | 6 |
sputum culture | 6 |
communicable diseases | 6 |
pneumoniae detection | 6 |
kidney injury | 6 |
fake drugs | 6 |
transgenic mice | 6 |
people living | 6 |
new york | 6 |
acute pancreatitis | 6 |
mean si | 6 |
pcr result | 6 |
cardiovascular disease | 6 |
tract infections | 6 |
influenza virus | 6 |
high school | 6 |
replacement therapy | 6 |
government officials | 6 |
supplemental oxygen | 6 |
mobile phones | 6 |
emergency department | 6 |
disease outbreak | 6 |
renal replacement | 6 |
diagnostic accuracy | 6 |
like illness | 6 |
white cell | 6 |
treat covid | 6 |
global pandemic | 6 |
health emergencies | 6 |
small number | 6 |
patient developed | 6 |
randomized trial | 6 |
lung diseases | 6 |
development goals | 6 |
hiv prevention | 6 |
military recruits | 6 |
south africa | 6 |
death among | 6 |
military training | 5 |
preparedness regarding | 5 |
active tb | 5 |
clinical specimens | 5 |
respiratory support | 5 |
blood pressure | 5 |
federal quarantine | 5 |
environmental contamination | 5 |
per million | 5 |
generation time | 5 |
among patients | 5 |
abnormal liver | 5 |
health professionals | 5 |
text view | 5 |
home quarantine | 5 |
disease surveillance | 5 |
health information | 5 |
substandard medicines | 5 |
regression analysis | 5 |
extended use | 5 |
thai army | 5 |
medical research | 5 |
time series | 5 |
care units | 5 |
influenza pandemic | 5 |
previous studies | 5 |
examination revealed | 5 |
emergency use | 5 |
final day | 5 |
severe emerging | 5 |
small bowel | 5 |
fast track | 5 |
symptomatic cases | 5 |
binding interface | 5 |
significantly higher | 5 |
medical history | 5 |
medical center | 5 |
lung abnormalities | 5 |
icu admission | 5 |
index case | 5 |
total number | 5 |
hygiene practices | 5 |
infected pneumonia | 5 |
first day | 5 |
septic shock | 5 |
although sars | 5 |
prescribed antibiotics | 5 |
plasmodium spp | 5 |
posterior values | 5 |
general secondary | 5 |
pulmonary disease | 5 |
full text | 5 |
drug development | 5 |
tension pneumothorax | 5 |
human respiratory | 5 |
positive patients | 5 |
coagulant state | 5 |
patients infected | 5 |
international health | 5 |
zika virus | 5 |
statistically significant | 5 |
first patient | 5 |
new coronavirus | 5 |
hiv patients | 5 |
training programs | 5 |
molecular characterization | 5 |
antiviral drugs | 5 |
viral etiology | 5 |
developed countries | 5 |
chest tube | 5 |
nosocomial transmission | 5 |
advanced general | 5 |
participating schools | 5 |
pharmaceutical companies | 5 |
united nations | 5 |
agents linked | 5 |
multiple sclerosis | 5 |
health news | 5 |
mouse model | 5 |
room air | 5 |
vivax malaria | 5 |
mice exhibited | 5 |
extrapulmonary organs | 5 |
artemisia spp | 5 |
will likely | 5 |
gastrointestinal tract | 5 |
evd outbreaks | 5 |
clinical manifestations | 5 |
one study | 5 |
disease pneumonia | 5 |
treatment centers | 5 |
staphylococcus aureus | 5 |
incident cases | 5 |
children aged | 5 |
southeast asia | 5 |
mobile phone | 5 |
diagnostic testing | 5 |
viral hepatitis | 5 |
family members | 5 |
clinical management | 5 |
lung zones | 5 |
data collection | 5 |
thrombotic complications | 5 |
two patients | 5 |
three countries | 5 |
secondary structure | 5 |
task force | 5 |
antimalarial drugs | 5 |
southern china | 5 |
skeletal muscle | 5 |
prevention tool | 5 |
two viruses | 5 |
supplemental file | 5 |
recent study | 5 |
viral loads | 5 |
hace transgenic | 5 |
reported cases | 5 |
underlying diseases | 5 |
effect size | 5 |
pharmaceutical interventions | 5 |
public face | 5 |
new guinea | 5 |
repurposed drugs | 5 |
contributed significantly | 5 |
childhood pneumonia | 5 |
white blood | 5 |
sex education | 5 |
antiretroviral treatment | 5 |
strongyloides stercoralis | 5 |
denv serotypes | 5 |
brain barrier | 5 |
randomised controlled | 5 |
closure policy | 5 |
hcq use | 5 |
multiple organ | 5 |
hubei province | 5 |
liver injury | 5 |
different genotypes | 5 |
viral titers | 5 |
supportive care | 5 |
credible interval | 5 |
patients without | 5 |
evd outbreak | 5 |
recovered patients | 5 |
densely populated | 5 |
lower chest | 5 |
treatment center | 5 |
secondary education | 5 |
nebraska medicine | 5 |
correct answers | 5 |
age category | 5 |
mycobacterium tuberculosis | 5 |
childcare centers | 5 |
antiretroviral therapy | 5 |
outbreak i | 5 |
healthcare facilities | 5 |
school vacation | 5 |
malaria among | 5 |
throat swabs | 5 |
monoclonal antibodies | 5 |
illness onset | 5 |
chronic lung | 5 |
without safely | 5 |
suspected cases | 5 |
holiday effect | 5 |
swab collection | 5 |
univariate analysis | 5 |
one patient | 5 |
health emergency | 5 |
quality assurance | 4 |
eosinophil count | 4 |
fake health | 4 |
indigenous cases | 4 |
behavior regarding | 4 |
information regarding | 4 |
early detection | 4 |
crazy paving | 4 |
fecal shedding | 4 |
pakistan electronic | 4 |
six patients | 4 |
acute covid | 4 |
severe malaria | 4 |
two different | 4 |
brunei darussalam | 4 |
media regulatory | 4 |
children younger | 4 |
pulmonary consolidations | 4 |
regulatory authority | 4 |
communicable disease | 4 |
genotype iv | 4 |
results showed | 4 |
time points | 4 |
novel covid | 4 |
obstructive pulmonary | 4 |
york times | 4 |
low levels | 4 |
care workers | 4 |
dry cough | 4 |
adaptive platform | 4 |
necrotizing encephalopathy | 4 |
conservative management | 4 |
may result | 4 |
clinical partner | 4 |
tissue distribution | 4 |
papua new | 4 |
day history | 4 |
coronavirus infections | 4 |
potential impact | 4 |
importation events | 4 |
regulatory authorities | 4 |
syncytial virus | 4 |
plasmodium falciparum | 4 |
cell cycle | 4 |
secondary schools | 4 |
electronic media | 4 |
infection among | 4 |
coronavirus research | 4 |
deaths worldwide | 4 |
invasive mechanical | 4 |
may cause | 4 |
pandemic preparedness | 4 |
patient care | 4 |
severe respiratory | 4 |
observational studies | 4 |
fragile health | 4 |
exp mj | 4 |
state governments | 4 |
inflammatory markers | 4 |
mice infected | 4 |
high mortality | 4 |
infection status | 4 |
important lessons | 4 |
community health | 4 |
affected areas | 4 |
several neurological | 4 |
organ dysfunction | 4 |
known exposure | 4 |
effective reproduction | 4 |
individual components | 4 |
si distribution | 4 |
may lead | 4 |
doubling time | 4 |
inadequate healthcare | 4 |
high viral | 4 |
hospital admission | 4 |
absolute eosinophil | 4 |
extrapulmonary tissue | 4 |
large quantities | 4 |
first days | 4 |
revealed bilateral | 4 |
hiv mtb | 4 |
correct answer | 4 |
side effects | 4 |
dengue patients | 4 |
situ evolution | 4 |
environmental surveillance | 4 |
mild respiratory | 4 |
confirmed rt | 4 |
early may | 4 |
polio vaccination | 4 |
health education | 4 |
prevention program | 4 |
exponential growth | 4 |
pandemic continues | 4 |
health officials | 4 |
normal range | 4 |
organ damage | 4 |
controlled trials | 4 |
suspected covid | 4 |
phylogenetic tree | 4 |
knowledge questions | 4 |
nebraska medical | 4 |
cloth masks | 4 |
disease progression | 4 |
abnormalities detected | 4 |
underlying lung | 4 |
investigational drugs | 4 |
evaluating repurposed | 4 |
line represents | 4 |
haemophilus influenzae | 4 |
human metapneumovirus | 4 |
week training | 4 |
combination arm | 4 |
also found | 4 |
pcr patients | 4 |
uri episodes | 4 |
various lung | 4 |
travel history | 4 |
federal isolation | 4 |
using pcr | 4 |
present two | 4 |
urgent need | 4 |
gene sequences | 4 |
cases reported | 4 |
severe outcomes | 4 |
informative prior | 4 |
emerging infectious | 4 |
respiratory syncytial | 4 |
similar results | 4 |
among different | 4 |
laboratory testing | 4 |
transverse colon | 4 |
publication bias | 4 |
postexposure prophylaxis | 4 |
longitudinal study | 4 |
human angiotensin | 4 |
rna viruses | 4 |
liver enzymes | 4 |
mg day | 4 |
clinical status | 4 |
income country | 4 |
vulnerable populations | 4 |
different months | 4 |
sample collection | 4 |
drinking water | 4 |
clinical series | 4 |
first school | 4 |
without proper | 4 |
etiological agents | 4 |
diagnostic test | 4 |
likert scale | 4 |
system involvement | 4 |
partner nebraska | 4 |
table shows | 4 |
th day | 4 |
mediastinal emphysema | 4 |
clinical evaluation | 4 |
viral infection | 4 |
pandemic caused | 4 |
health promoting | 4 |
syndrome associated | 4 |
global supply | 4 |
control efforts | 4 |
medical care | 4 |
pandemic influenza | 4 |
parasitic ntds | 4 |
among positive | 4 |
international law | 4 |
nucleic acid | 4 |
sustainable development | 4 |
four components | 4 |
high rates | 4 |
health security | 4 |
large outbreak | 4 |
million cases | 4 |
normally distributed | 4 |
intravenous immunoglobulin | 4 |
tropical settings | 4 |
million individuals | 4 |
study provides | 4 |
frequent symptom | 4 |
metabolic acidosis | 4 |
early identification | 4 |
migrant laborers | 4 |
muscle injury | 4 |
patients hospitalized | 4 |
hace gene | 4 |
mandatory quarantine | 4 |
preliminary report | 4 |
study aimed | 4 |
included patients | 4 |
regression analyses | 4 |
human coronaviruses | 4 |
study period | 4 |
heart rate | 4 |
intervention groups | 4 |
performed using | 4 |
alanine aminotransferase | 4 |
study demonstrated | 4 |
igg antibodies | 4 |
critical questions | 4 |
mouse ace | 4 |
five studies | 4 |
severe coronavirus | 4 |
shared latrine | 4 |
information sources | 4 |
usd piece | 4 |
second school | 4 |
three cases | 4 |
case numbers | 4 |
clinical efficacy | 4 |
fecal contamination | 4 |
malaria control | 4 |
compassionate use | 4 |
medical countermeasures | 4 |
potential risk | 4 |
marked heterogeneity | 4 |
health facilities | 4 |
pulmonary tuberculosis | 4 |
tests per | 4 |
moderate covid | 4 |
notifiable disease | 4 |
vaccine hesitancy | 4 |
associated acute | 4 |
muscle pain | 4 |
managed conservatively | 4 |
coronavirus outbreak | 4 |
patients treated | 4 |
chronic obstructive | 4 |
less likely | 4 |
intervention study | 4 |
mouse strain | 4 |
present study | 4 |
active ingredient | 4 |
training period | 4 |
cruise ship | 4 |
lineage i | 4 |
lus findings | 4 |
treatment facilities | 4 |
days following | 4 |
national guidelines | 4 |
mtb coinfection | 4 |
may include | 4 |
multiplex pcr | 4 |
therapeutic options | 4 |
median values | 4 |
asymptomatic individuals | 4 |
abdominal pain | 4 |
epidemic situation | 4 |
international agencies | 3 |
data indicate | 3 |
pathogens research | 3 |
antibody titers | 3 |
asymptomatic ratio | 3 |
main effects | 3 |
global impact | 3 |
misleading information | 3 |
higher peep | 3 |
severe sars | 3 |
first wave | 3 |
extrapulmonary manifestation | 3 |
first week | 3 |
weekly number | 3 |
mers epidemic | 3 |
natural ventilation | 3 |
primary symptoms | 3 |
interim analysis | 3 |
evaluate efficacy | 3 |
fit testing | 3 |
traditional medicines | 3 |
care treatment | 3 |
potential mechanism | 3 |
release syndrome | 3 |
detection technologies | 3 |
travel bans | 3 |
increased susceptibility | 3 |
murine model | 3 |
severity score | 3 |
genetic diversity | 3 |
acute hemorrhagic | 3 |
case identification | 3 |
solitary tract | 3 |
among military | 3 |
epidemic control | 3 |
increased corruption | 3 |
local mosquito | 3 |
pooled proportion | 3 |
general community | 3 |
diagnosed cases | 3 |
vessel stroke | 3 |
dengue epidemic | 3 |
viral clearance | 3 |
viruskenner education | 3 |
treating covid | 3 |
vacation effect | 3 |
cyclic epidemics | 3 |
effect sizes | 3 |
global covid | 3 |
three main | 3 |
genetic predisposition | 3 |
bowel loops | 3 |
medical sciences | 3 |
human immunodeficiency | 3 |
hace mouse | 3 |
way analysis | 3 |
occurred yearly | 3 |
testing capacity | 3 |
accelerate treatment | 3 |
school framework | 3 |
independent newspapers | 3 |
rapid response | 3 |
hemoptoic sputum | 3 |
medicinal plants | 3 |
quarantine order | 3 |
clinical outcomes | 3 |
probable bat | 3 |
triple combination | 3 |
healthcare providers | 3 |
independently associated | 3 |
immunosuppressive treatment | 3 |
statistical significance | 3 |
therapy maintains | 3 |
emerging evidence | 3 |
army recruits | 3 |
orange line | 3 |
reducing transmission | 3 |
new infections | 3 |
severe anemia | 3 |
days later | 3 |
therapeutic effects | 3 |
test combination | 3 |
promoting school | 3 |
epidemic curve | 3 |
commonly found | 3 |
use authorization | 3 |
therapeutic algorithm | 3 |
asymptomatic carriers | 3 |
upper middle | 3 |
related knowledge | 3 |
fourth school | 3 |
presenting symptoms | 3 |
military settings | 3 |
participating countries | 3 |
quarantined persons | 3 |
seven studies | 3 |
quarantine unit | 3 |
prior monotherapy | 3 |
demonstrate limited | 3 |
eradication programs | 3 |
descriptive study | 3 |
based education | 3 |
trace approach | 3 |
bilateral pneumothorax | 3 |
mobile health | 3 |
clinical study | 3 |
bowel wall | 3 |
microbiological findings | 3 |
treatment options | 3 |
substantial reductions | 3 |
swab date | 3 |
endothelial cells | 3 |
existing health | 3 |
male gender | 3 |
nosocomial infection | 3 |
isolation facility | 3 |
treatment evaluations | 3 |
way forward | 3 |
mean score | 3 |
molecular characteristics | 3 |
potent inhibitor | 3 |
ebola epidemic | 3 |
drug trial | 3 |
host cells | 3 |
gastrointestinal infection | 3 |
combining two | 3 |
epidemiological investigation | 3 |
future pandemics | 3 |
least one | 3 |
opening remarks | 3 |
past medical | 3 |
viral respiratory | 3 |
nurses working | 3 |
infections among | 3 |
spurious falsely | 3 |
imaging findings | 3 |
biocontainment unit | 3 |
growth rate | 3 |
routine use | 3 |
positive denv | 3 |
ns antigen | 3 |
research network | 3 |
sexual health | 3 |
inflammatory cell | 3 |
bullae formation | 3 |
neurological symptoms | 3 |
higher frequency | 3 |
cov rna | 3 |
international development | 3 |
study conducted | 3 |
conspiracy narratives | 3 |
surveillance data | 3 |
reporting system | 3 |
early phase | 3 |
two days | 3 |
combination strategies | 3 |
tangerang district | 3 |
symptomatic covid | 3 |
intranasally inoculated | 3 |
quarantine stations | 3 |
patients described | 3 |
capital city | 3 |
healthcare professionals | 3 |
short time | 3 |
mask policies | 3 |
medical facilities | 3 |
evaluating monotherapies | 3 |
mean percentage | 3 |
member states | 3 |
hygiene techniques | 3 |
venous thromboembolism | 3 |
age pattern | 3 |
medical equipment | 3 |
including hiv | 3 |
national quarantine | 3 |
associated coronavirus | 3 |
previous outbreaks | 3 |
invasive ventilation | 3 |
diffuse ground | 3 |
sectional study | 3 |
lead organization | 3 |
coronavirus cases | 3 |
awake prone | 3 |
private medicals | 3 |
recently published | 3 |
first time | 3 |
patients requiring | 3 |
press release | 3 |
animal model | 3 |
patients differed | 3 |
percent weight | 3 |
air travel | 3 |
antiviral treatment | 3 |
nasal congestion | 3 |
health conditions | 3 |
also observed | 3 |
disease caused | 3 |
mtb coinfections | 3 |
leading serotype | 3 |
teacher interviews | 3 |
zones examined | 3 |
tested acute | 3 |
pressing need | 3 |
special pathogens | 3 |
serial interval | 3 |
human adenovirus | 3 |
sectional survey | 3 |
may reduce | 3 |
large country | 3 |
prevention intervention | 3 |
institutional review | 3 |
square test | 3 |
market price | 3 |
rapid test | 3 |
significant clinical | 3 |
mice transgenic | 3 |
wide variety | 3 |
interval ci | 3 |
first weeks | 3 |
common symptoms | 3 |
four studies | 3 |
increased knowledge | 3 |
two studies | 3 |
kermanshah university | 3 |
infected people | 3 |
pcr testing | 3 |
study protocol | 3 |
last century | 3 |
contact cases | 3 |
day postinfection | 3 |
students learned | 3 |
dimer levels | 3 |
molecular epidemiology | 3 |
combat covid | 3 |
effective treatments | 3 |
power analysis | 3 |
convalescent plasma | 3 |
real time | 3 |
enjoyed working | 3 |
health sector | 3 |
interstitial lung | 3 |
lived separately | 3 |
study clinical | 3 |
multiplex real | 3 |
storm syndromes | 3 |
chinese center | 3 |
clinical disease | 3 |
case suggests | 3 |
decreased air | 3 |
mask wearing | 3 |
poverty line | 3 |
anecdotal use | 3 |
patients diagnosed | 3 |
plasmodium vivax | 3 |
disease outbreaks | 3 |
chest pain | 3 |
strongyloides serology | 3 |
known underlying | 3 |
thai hospitals | 3 |
ill covid | 3 |
early diagnosis | 3 |
pneumococcus detection | 3 |
viral titer | 3 |
relatively small | 3 |
immunodeficiency virus | 3 |
several years | 3 |
initial presentation | 3 |
chest examination | 3 |
since late | 3 |
illness among | 3 |
oxygen requirement | 3 |
old woman | 3 |
global spread | 3 |
health technology | 3 |
groups regarding | 3 |
although covid | 3 |
life cycle | 3 |
wear face | 3 |
time rt | 3 |
public wearing | 3 |
active ingredients | 3 |
adequate training | 3 |
monotherapy data | 3 |
industrial scale | 3 |
changing epidemiology | 3 |
counterfeit medical | 3 |
th response | 3 |
research findings | 3 |
may serve | 3 |
cytokine release | 3 |
denv igg | 3 |
drug interactions | 3 |
second case | 3 |
igg titer | 3 |
multiple linear | 3 |
old patient | 3 |
african nations | 3 |
lethal infection | 3 |
clinical diagnosis | 3 |
three patients | 3 |
accelerated development | 3 |
life science | 3 |
global fund | 3 |
pregnant women | 3 |
prior distributions | 3 |
san lorenzo | 3 |
confirmative rt | 3 |
save lives | 3 |
first use | 3 |
china clinical | 3 |
generally speaking | 3 |
breaths minute | 3 |
educational intervention | 3 |
cerebrospinal fluid | 3 |
group needed | 3 |
education modules | 3 |
second week | 3 |
pandemic situation | 3 |
road map | 3 |
good governance | 3 |
dengue ns | 3 |
condition improved | 3 |
local community | 3 |
showed bilateral | 3 |
concern regarding | 3 |
appropriate use | 3 |
categorical variables | 3 |
effective treatment | 3 |
lineages i | 3 |
laboratory diagnosis | 3 |
bat origin | 3 |
track multiplex | 3 |
visibly soiled | 3 |
businessmen increased | 3 |
past decade | 3 |
national lockdown | 3 |
clinical presentation | 3 |
treatment protocol | 3 |
dyspnea day | 3 |
scored higher | 3 |
every day | 3 |
china covid | 3 |
stool ova | 3 |
considered significant | 3 |
basic sanitation | 3 |
interim guidance | 3 |
highly variable | 3 |
supportive resources | 3 |
mask use | 3 |
falsified chloroquine | 3 |
resource settings | 3 |
quality control | 3 |
beats minute | 3 |
gastrointestinal manifestations | 3 |
hospital discharge | 3 |
multipronged approach | 3 |
deceased patients | 3 |
counterfeit drugs | 3 |
rational use | 3 |
left untreated | 3 |
mainland china | 3 |
hospital stay | 3 |
medical supplies | 3 |
apasl covid | 3 |
drug combinations | 3 |
possible complication | 3 |
point likert | 3 |
scientific profiles | 3 |
nonrandomized intervention | 3 |
posttest per | 3 |
additional cases | 3 |
individual component | 3 |
interstitial pneumonia | 3 |
day later | 3 |
elevated liver | 3 |
backward stepwise | 3 |
blood cultures | 3 |
monoclonal antibody | 3 |
health infrastructures | 3 |
keep politics | 3 |
open defecation | 3 |
gabriel network | 3 |
dengue infections | 3 |
west african | 3 |
national institute | 3 |
elderly patients | 3 |
suspect ward | 3 |
median number | 3 |
trials evaluating | 3 |
inclusion criteria | 3 |
media briefing | 3 |
lung involvement | 3 |
hypotension requiring | 3 |
interferon beta | 3 |
hiv control | 3 |
time reverse | 3 |
module started | 3 |
report sars | 3 |
medical workers | 3 |
abdomen showed | 3 |
significant interaction | 3 |
prospective cohort | 3 |
risk management | 3 |
endemic regions | 3 |
ace receptors | 3 |
suspected diagnosed | 3 |
active case | 3 |
saudi arabia | 3 |
community engagement | 3 |
known risk | 3 |
exposure period | 3 |
hospitalised patients | 3 |
latin america | 3 |
traditional medicine | 3 |
study sars | 3 |
group consisted | 3 |
analysis revealed | 3 |
two substitutions | 3 |
linear regression | 3 |
proper handwashing | 3 |
typical year | 3 |
rhabditiform larvae | 3 |
approach addressing | 3 |
global disease | 3 |
two weeks | 3 |
hypoxemic children | 3 |
requiring oxygen | 3 |
also present | 3 |
control study | 3 |
potential risks | 3 |
hiv services | 3 |
preparedness plans | 3 |
treatment effect | 3 |
tomography scan | 3 |
overall mortality | 3 |
pneumonia outbreak | 3 |
toward covid | 3 |
less commonly | 3 |
malaria transmission | 3 |
herpes simplex | 3 |
therapeutic effect | 3 |
kigali modification | 3 |
platform trial | 3 |
ebola outbreak | 3 |
phase iii | 3 |
pulmonary infection | 3 |
tobacco control | 3 |
west africa | 3 |
outbreak associated | 3 |
study also | 3 |
denv isolated | 3 |
every hours | 3 |
frontline healthcare | 3 |
additional information | 3 |
still detect | 3 |
bacterial colonization | 3 |
cycle dynamics | 3 |
i interferon | 3 |
acute inflammation | 3 |
incidence data | 3 |
also positive | 3 |
news channels | 3 |
admission sera | 3 |
although viral | 3 |
clinical case | 3 |
third week | 3 |
high igg | 3 |
long term | 3 |
prevent virus | 3 |
hospital stays | 3 |
annua extracts | 3 |
human services | 3 |
multicenter cohort | 3 |
africa region | 3 |
surgical masks | 3 |
control strategies | 3 |
without pulmonary | 3 |
conspiracy theory | 3 |
disease reporting | 3 |
pulmonary diseases | 3 |
viruskenner module | 3 |
variable pathways | 3 |
new fever | 3 |
tenth evd | 3 |
consider cytokine | 3 |
cd cell | 3 |
whole blood | 3 |
emerging pathogens | 3 |
transmission via | 3 |
reliable information | 3 |
pcr assay | 3 |
common cold | 3 |
four serotypes | 3 |
mouse models | 3 |
transmission routes | 3 |
laborers decreased | 3 |
infections may | 3 |
healthcare infrastructure | 3 |
factors play | 3 |
major cause | 3 |
public awareness | 3 |
lower mortality | 3 |
research program | 3 |
exact test | 3 |
quality assessment | 3 |
develop formulations | 3 |
antibiotic use | 3 |
specific primers | 3 |
clinical predictors | 3 |
young children | 3 |
health zones | 3 |
respiratory specimens | 3 |
high temperature | 3 |
modelling study | 3 |
management strategies | 3 |
repurposed treatments | 3 |
severe dengue | 3 |
oral sars | 3 |
game changer | 3 |
alveolar septal | 3 |
healthcare settings | 3 |
transgenic mouse | 3 |
ivermectin inhibits | 3 |
mean age | 3 |
one case | 3 |
social sciences | 3 |
viral myositis | 3 |
missing values | 3 |
imported database | 3 |
circulated continuously | 3 |
hfmd outbreaks | 3 |
nasal samples | 3 |
virus shedding | 3 |
viral control | 3 |
examination showed | 3 |
previously described | 3 |
study date | 3 |
national center | 3 |
viral antigen | 3 |
recovery trial | 3 |
second patient | 3 |
lung lesions | 3 |
cases occurred | 3 |
secondary cases | 3 |
adenovirus type | 3 |
corona virus | 3 |
septal thickening | 3 |
unclear whether | 3 |
specific pathogens | 3 |
bacterial infection | 3 |
five cities | 3 |
testing resources | 3 |
air entry | 3 |
will help | 3 |
review board | 3 |
samples tested | 3 |
younger patients | 3 |
recently reported | 3 |
available literature | 3 |
table presents | 3 |
domain iii | 3 |
noncommunicable diseases | 3 |
vitro concentrations | 3 |
antiviral activities | 3 |
effects permits | 3 |
causative agent | 3 |
respiratory diseases | 3 |
age groups | 3 |
care facilities | 3 |
manage covid | 3 |
peripheral distribution | 3 |
median duration | 3 |
determine whether | 3 |
developed acute | 3 |
may contribute | 3 |
confidence interval | 3 |
false claims | 3 |
different countries | 3 |
virus transmission | 3 |
evolutionary lineage | 3 |
multiple introductions | 3 |
cases among | 3 |
using similar | 3 |
following covid | 3 |
imaging modality | 3 |
medicine quality | 3 |
dimer level | 3 |
global public | 3 |
dutch intervention | 3 |
presented pneumothorax | 3 |
substandard drugs | 3 |
bilateral spontaneous | 3 |
intense transmission | 3 |
darunavir ritonavir | 3 |
among covid | 3 |
hepatitis virus | 3 |
aspartate aminotransferase | 3 |
district hospital | 3 |
public spaces | 3 |
maintains scientific | 3 |
included studies | 3 |
major causative | 3 |
well known | 3 |
royal thai | 3 |
lineage iii | 3 |
endemic area | 3 |
based hiv | 3 |
evaluated patients | 3 |
study design | 3 |
sanitation shortfalls | 3 |
private hospitals | 3 |
case detection | 3 |
severe manifestations | 3 |
written informed | 3 |
several studies | 3 |
generic medicines | 3 |
lineage ii | 3 |
among young | 3 |
guangdong since | 3 |
circle graph | 3 |
ace expression | 3 |
containment measures | 3 |
infectious agents | 3 |
genetic defects | 3 |
isolation orders | 3 |
local contact | 3 |
universal masking | 3 |
international convention | 3 |
indonesian participants | 3 |
first step | 3 |
therapeutic dose | 2 |
recently returned | 2 |
including age | 2 |
level approaches | 2 |
significant increase | 2 |
safely store | 2 |
virus serotype | 2 |
knowledge among | 2 |
milder disease | 2 |
forming units | 2 |
unpublished data | 2 |
directly affected | 2 |
representative strains | 2 |
hospital death | 2 |
arbitrarily selected | 2 |
influenza seroconversion | 2 |
reports describing | 2 |
might lead | 2 |
evidence shows | 2 |
tpsf ca | 2 |
synergistic epidemics | 2 |
electron microscopy | 2 |
world trade | 2 |
lower lobes | 2 |
fourth schools | 2 |
will play | 2 |
suggest genetic | 2 |
hiv epidemic | 2 |
health policy | 2 |
media platforms | 2 |
plaque assays | 2 |
clinical research | 2 |
old children | 2 |
recovered covid | 2 |
knowledge regarding | 2 |
reported questionnaires | 2 |
model validity | 2 |
acquired immunodeficiency | 2 |
may need | 2 |
demographic characteristics | 2 |
negative pressure | 2 |
human brain | 2 |
improved infection | 2 |
among suspected | 2 |
virus environmental | 2 |
purification therapy | 2 |
three courses | 2 |
pneumonia severity | 2 |
will require | 2 |
assistant secretary | 2 |
seriously ill | 2 |
extremity deep | 2 |
received covid | 2 |
outside hubei | 2 |
died within | 2 |
nursing facility | 2 |
diamond princess | 2 |
increasingly recognized | 2 |
electrolyte disorders | 2 |
saliva samples | 2 |
fake medicines | 2 |
severe falciparum | 2 |
multiple viruses | 2 |
neurological aspects | 2 |
preventing new | 2 |
protection agency | 2 |
additional testing | 2 |
fecal viral | 2 |
methodological flaws | 2 |
pneumonia incidence | 2 |
patients receive | 2 |
emerging data | 2 |
also conducted | 2 |
mass gathering | 2 |
copies mm | 2 |
spike protein | 2 |
epidemic patterns | 2 |
quantitative variables | 2 |
current status | 2 |
cases decreased | 2 |
golden syrian | 2 |
pressure ventilation | 2 |
first patients | 2 |
modeling studies | 2 |
challenge dose | 2 |
week prior | 2 |
care team | 2 |
report spontaneous | 2 |
time period | 2 |
easily introduced | 2 |
data suggested | 2 |
data protection | 2 |
medicine regulatory | 2 |
severe complications | 2 |
infected case | 2 |
antiviral combination | 2 |
quite common | 2 |
per year | 2 |
time pcr | 2 |
low molecular | 2 |
antimalarial drug | 2 |
corresponding author | 2 |
relevant therapeutic | 2 |
training courses | 2 |
chloroquine products | 2 |
last years | 2 |
late complication | 2 |
used appropriately | 2 |
diagnostic value | 2 |
significantly related | 2 |
school education | 2 |
persistent pneumothorax | 2 |
funding decisions | 2 |
treatment effects | 2 |
compound repurposing | 2 |
substandard spurious | 2 |
essential drugs | 2 |
detected within | 2 |
bioactive compounds | 2 |
virus detected | 2 |
first study | 2 |
initiate research | 2 |
precaution recommendations | 2 |
operating procedures | 2 |
authors described | 2 |
must demonstrate | 2 |
get infected | 2 |
information software | 2 |
greater impact | 2 |
temperate settings | 2 |
product distribution | 2 |
excess mortality | 2 |
get treatment | 2 |
dutch system | 2 |
tomography angiography | 2 |
serum antibody | 2 |
many less | 2 |
cooperative work | 2 |
timely diagnosis | 2 |
hamster model | 2 |
evolutionary genetics | 2 |
potential game | 2 |
white house | 2 |
vn nrm | 2 |
abnormal chest | 2 |
continuous fever | 2 |
respiratory coronaviruses | 2 |
will need | 2 |
without basic | 2 |
different sites | 2 |
sars cov | 2 |
international travel | 2 |
promoting safe | 2 |
correlation coefficients | 2 |
economic hardships | 2 |
analyzed using | 2 |
nurses indicated | 2 |
described previously | 2 |
within weeks | 2 |
awareness regarding | 2 |
pharmaceutical supply | 2 |
suppresses host | 2 |
viruses detected | 2 |
clinical samples | 2 |
eliminate malaria | 2 |
common control | 2 |
avoid complications | 2 |
health policies | 2 |
plus ritonavir | 2 |
person transmission | 2 |
indian population | 2 |
bowel sounds | 2 |
modern years | 2 |
corticosteroid use | 2 |
gamma distribution | 2 |
vv zc | 2 |
without access | 2 |
hydroxychloroquine plus | 2 |
severely ill | 2 |
dark urine | 2 |
grand illusion | 2 |
contaminated water | 2 |
multiplex polymerase | 2 |
literature shows | 2 |
viral diseases | 2 |
causing covid | 2 |
eye closure | 2 |
protein function | 2 |
disease pathogenesis | 2 |
inappropriate use | 2 |
one camp | 2 |
isolation room | 2 |
safety precautions | 2 |
lrz bdx | 2 |
breathing difficulty | 2 |
remained seronegative | 2 |
tissues affected | 2 |
personal belongings | 2 |
risk sars | 2 |
clinical score | 2 |
local epidemics | 2 |
risk groups | 2 |
df outbreak | 2 |
scientific profile | 2 |
local prevalence | 2 |
systematic literature | 2 |
survey found | 2 |
adaptive designs | 2 |
including school | 2 |
national university | 2 |
confidence intervals | 2 |
report two | 2 |
outbreak size | 2 |
early days | 2 |
less developed | 2 |
guyon university | 2 |
leading cause | 2 |
viral transmission | 2 |
also commonly | 2 |
data source | 2 |
first reported | 2 |
younger age | 2 |
first half | 2 |
parasitic infection | 2 |
several african | 2 |
mass media | 2 |
data extraction | 2 |
knowledge score | 2 |
across cohorts | 2 |
sell life | 2 |
two laboratories | 2 |
widely used | 2 |
three groups | 2 |
lineage iv | 2 |
associated features | 2 |
preventive anticoagulation | 2 |
abnormal coagulation | 2 |
covid pneumonia | 2 |
tb diagnosed | 2 |
systems become | 2 |
extensively circulated | 2 |
active pharmaceutical | 2 |
medicines fall | 2 |
coronavirus causes | 2 |
hospital level | 2 |
prospective studies | 2 |
open label | 2 |
combination selection | 2 |
cases detected | 2 |
silent circulation | 2 |
important factor | 2 |
remained hospitalized | 2 |
international trade | 2 |
continental spread | 2 |
expected number | 2 |
short buccal | 2 |
care measures | 2 |
military trainees | 2 |
vivax infection | 2 |
tissue factor | 2 |
using rdt | 2 |
relatively young | 2 |
seek medical | 2 |
health crisis | 2 |
infected cases | 2 |
rapidly spread | 2 |
without evidence | 2 |
evolution database | 2 |
mean white | 2 |
bayesian models | 2 |
muscle weakness | 2 |
asymptomatic children | 2 |
effective medicines | 2 |
malaria map | 2 |
epidemic outbreaks | 2 |
illness cases | 2 |
highest area | 2 |
intervention among | 2 |
olfactory neuropathy | 2 |
epithelial cell | 2 |
evolutionary analysis | 2 |
use medical | 2 |
five mice | 2 |
finding amid | 2 |
laboratory results | 2 |
alberti minutti | 2 |
test results | 2 |
describe two | 2 |
higher rates | 2 |
care settings | 2 |
asymptomatic sars | 2 |
many people | 2 |
clinical presentations | 2 |
surpassed million | 2 |
pharmacology expert | 2 |
disease patients | 2 |
scientific brief | 2 |
influenza infection | 2 |
may yield | 2 |
global south | 2 |
internal consistency | 2 |
antibody responses | 2 |
structural protein | 2 |
using reverse | 2 |
main limitations | 2 |
asymptomatic infection | 2 |
newspapers nigeria | 2 |
enrolled patients | 2 |
requiring mechanical | 2 |
crp level | 2 |
barr virus | 2 |
authoritative guidance | 2 |
late arrival | 2 |
interquartile range | 2 |
selected outbreaks | 2 |
ace promoter | 2 |
comprehensive sex | 2 |
line irregularities | 2 |
chain disruption | 2 |
limited resources | 2 |
lost around | 2 |
timely initiation | 2 |
interaction effects | 2 |
perfusion scintigraphy | 2 |
evidence suggests | 2 |
hematogenous route | 2 |
will increase | 2 |
remaining patients | 2 |
renal injury | 2 |
polio vaccine | 2 |
acutely ill | 2 |
treatment adopted | 2 |
medrxiv covid | 2 |
test negative | 2 |
foreign minister | 2 |
viral pathogens | 2 |
averting deaths | 2 |
strategy may | 2 |
conducted using | 2 |
sexual intercourse | 2 |
focus diagnostics | 2 |
track diagnostics | 2 |
world economy | 2 |
influenza activity | 2 |
significant predictors | 2 |
studies suggest | 2 |
evd response | 2 |
radiation exposure | 2 |
also detected | 2 |
phylogenetic methods | 2 |
retrospective case | 2 |
help greatly | 2 |
los angeles | 2 |
adult inpatients | 2 |
jeffery cutter | 2 |
observed high | 2 |
significant number | 2 |
communication strategy | 2 |
information system | 2 |
local applicability | 2 |
right lung | 2 |
mtb latent | 2 |
high index | 2 |
ncov infection | 2 |
ili episodes | 2 |
multivariate analysis | 2 |
infrastructure solutions | 2 |
coagulation parameters | 2 |
received hcq | 2 |
enterocytes may | 2 |
extra attention | 2 |
different types | 2 |
pose challenges | 2 |
medicines regulation | 2 |
condom use | 2 |
develop drugs | 2 |
standard operating | 2 |
covid treatment | 2 |
sars outbreak | 2 |
united arab | 2 |
indian states | 2 |
health infrastructure | 2 |
limited effective | 2 |
efficacy data | 2 |
gene expression | 2 |
functional receptor | 2 |
negative si | 2 |
limited availability | 2 |
permanent residents | 2 |
infected erythrocytes | 2 |
complementary therapeutic | 2 |
bias assessment | 2 |
external funding | 2 |
equatorial guinea | 2 |
individual efficacy | 2 |
exponential increase | 2 |
also reported | 2 |
complication necessitates | 2 |
every month | 2 |
acute viral | 2 |
lower level | 2 |
center campus | 2 |
negative patients | 2 |
international standards | 2 |
community screening | 2 |
financial resources | 2 |
community settings | 2 |
transmission potential | 2 |
potential effect | 2 |
two adult | 2 |
descriptive statistics | 2 |
immunological effects | 2 |
rate breaths | 2 |
swabs collected | 2 |
large outbreaks | 2 |
immunodiagnostic tests | 2 |
will also | 2 |
health intervention | 2 |
care alone | 2 |
health survey | 2 |
clinical characterization | 2 |
tb notifications | 2 |
female worms | 2 |
london school | 2 |
pilot study | 2 |
next day | 2 |
behavior questions | 2 |
ussd code | 2 |
separate hospital | 2 |
affordable diagnostic | 2 |
disposed inappropriately | 2 |
sequence analysis | 2 |
third part | 2 |
oxygen via | 2 |
dose corticosteroids | 2 |
specific antibody | 2 |
strongly disagree | 2 |
kmo value | 2 |
median weight | 2 |
polyneuritis cranialis | 2 |
flouting lockdown | 2 |
fold increased | 2 |
syndrome virus | 2 |
sided pneumothorax | 2 |
tissue bank | 2 |
solidarity trial | 2 |
counterfeit drug | 2 |
rna polymerase | 2 |
quality surveillance | 2 |
clinically stable | 2 |
pandemic advice | 2 |
bilateral lung | 2 |
information gain | 2 |
many others | 2 |
qt interval | 2 |
similar cases | 2 |
dengue infection | 2 |
underwent one | 2 |
recognizing paralytic | 2 |
repeat blood | 2 |
walter reed | 2 |
federal regulations | 2 |
implementation science | 2 |
largest vaccine | 2 |
highly conserved | 2 |
disease requiring | 2 |
amino acid | 2 |
strategy using | 2 |
related cases | 2 |
available evidence | 2 |
ventilatory support | 2 |
elevated body | 2 |
first hours | 2 |
reduce disease | 2 |
supported international | 2 |
falsely labeled | 2 |
murine hepatitis | 2 |
single dose | 2 |
front line | 2 |
fold rise | 2 |
several days | 2 |
combination platform | 2 |
triple threat | 2 |
targeted continuous | 2 |
including one | 2 |
immunodeficiency syndrome | 2 |
mental status | 2 |
sewage overflows | 2 |
studies using | 2 |
peer review | 2 |
clear epidemiological | 2 |
rapidly increasing | 2 |
denv outbreak | 2 |
three age | 2 |
group showed | 2 |
review population | 2 |
long view | 2 |
care management | 2 |
tumor necrosis | 2 |
data available | 2 |
pneumonia sars | 2 |
preliminary analysis | 2 |
based screening | 2 |
first survey | 2 |
type isolated | 2 |
combination offers | 2 |
acute necrotizing | 2 |
disease status | 2 |
several aspects | 2 |
health approach | 2 |
tropical countries | 2 |
entomological characteristics | 2 |
literature search | 2 |
index cases | 2 |
following day | 2 |
prominent genital | 2 |
characterization protocol | 2 |
facebook page | 2 |
comparing posterior | 2 |
asian settings | 2 |
following treatment | 2 |
controlled clinical | 2 |
particularly among | 2 |
gastrointestinal complications | 2 |
pneumothorax developed | 2 |
repeat ct | 2 |
pay attention | 2 |
potential covid | 2 |
time saving | 2 |
several hundred | 2 |
cases may | 2 |
changes per | 2 |
zc gd | 2 |
ray revealed | 2 |
billion people | 2 |
angiography pulmonary | 2 |
nucleus ambiguous | 2 |
pandemic severity | 2 |
antimicrobial resistance | 2 |
also likely | 2 |
presymptomatic cases | 2 |
high i | 2 |
bleb resection | 2 |
biological research | 2 |
mild clinical | 2 |
cochrane review | 2 |
pneumonia induced | 2 |
coronavirus nsp | 2 |
molecular tests | 2 |
vascular endothelial | 2 |
recent secondary | 2 |
multiple geographies | 2 |
urban centers | 2 |
testing strategy | 2 |
situation report | 2 |
transcription polymerase | 2 |
negative binomial | 2 |
human papillomavirus | 2 |
inflammatory mediators | 2 |
education programme | 2 |
ferritin levels | 2 |
vital status | 2 |
gold lines | 2 |
higher probability | 2 |
affordable tools | 2 |
analysis software | 2 |
learning curve | 2 |
mg oral | 2 |
aberrant immune | 2 |
spread worldwide | 2 |
stool analysis | 2 |
educational factors | 2 |
medical unit | 2 |
environments create | 2 |
adults aged | 2 |
different regions | 2 |
denv since | 2 |
cases since | 2 |
initial covid | 2 |
stern measures | 2 |
plastic box | 2 |
lymphocyte count | 2 |
receptor recognition | 2 |
informal settlements | 2 |
previously reported | 2 |
antitrypsin deficiency | 2 |
north america | 2 |
dengue type | 2 |
negative sepsis | 2 |
closure effect | 2 |
mainly mild | 2 |
prevent infection | 2 |
report describes | 2 |
will go | 2 |
regarding sars | 2 |
considerations regarding | 2 |
low confidence | 2 |
sudden onset | 2 |
effective interventions | 2 |
requiring norepinephrine | 2 |
health response | 2 |
impact assessment | 2 |
exhalation valves | 2 |
chemical analysis | 2 |
za hi | 2 |
extrapulmonary complication | 2 |
approach may | 2 |
another study | 2 |
health consequences | 2 |
new lineages | 2 |
questionnaires used | 2 |
older adults | 2 |
countries worldwide | 2 |
quality assessments | 2 |
might explain | 2 |
also data | 2 |
miami herald | 2 |
aldosterone system | 2 |
virtual care | 2 |
innate immunity | 2 |
virus interaction | 2 |
drug manufacturing | 2 |
community needs | 2 |
many health | 2 |
princess cruise | 2 |
health supply | 2 |
traditional medicinal | 2 |
healthcare crisis | 2 |
previously healthy | 2 |
initial cases | 2 |
personal hygiene | 2 |
rapidly evolving | 2 |
care ultrasonography | 2 |
detected using | 2 |
knr mat | 2 |
coagulation cascade | 2 |
necessary measures | 2 |
followed twice | 2 |
angiotensin ii | 2 |
asymptomatic proportion | 2 |
fisher syndrome | 2 |
achieving good | 2 |
global center | 2 |
intubated patients | 2 |
specific tests | 2 |
laboratory tests | 2 |
oxygen support | 2 |
one example | 2 |
indonesian school | 2 |
anxiety disorder | 2 |
kidney disease | 2 |
randomized trials | 2 |
hospital care | 2 |
general population | 2 |
average number | 2 |
poisson model | 2 |
systematic analysis | 2 |
complete blood | 2 |
validity assessed | 2 |
nasal swabs | 2 |
driving pressure | 2 |
ground glass | 2 |
patient died | 2 |
patient safety | 2 |
infectorinfectee pairs | 2 |
commonly reported | 2 |
seventh day | 2 |
nonstructural proteins | 2 |
affected health | 2 |
participants provided | 2 |
several reports | 2 |
masks may | 2 |
mitigation strategies | 2 |
generalized muscle | 2 |
adaptive combination | 2 |
reasons might | 2 |
systemic inflammatory | 2 |
independent variables | 2 |
antibody testing | 2 |
worth noting | 2 |
drug epidemic | 2 |
local healthcare | 2 |
differences among | 2 |
nasal cannula | 2 |
buccal canal | 2 |
spot checks | 2 |
crucial role | 2 |
active compounds | 2 |
utmost importance | 2 |
ibm spss | 2 |
infection rates | 2 |
oral pathogens | 2 |
including malaria | 2 |
study detection | 2 |
acute lung | 2 |
ciliated epithelial | 2 |
identify high | 2 |
french data | 2 |
detect individual | 2 |
evaluating combination | 2 |
secondary infections | 2 |
child health | 2 |
possible underlying | 2 |
pseudorabies virus | 2 |
hiv protease | 2 |
medicine supply | 2 |
group included | 2 |
severe infection | 2 |
adenovirus types | 2 |
technasium network | 2 |
closed settings | 2 |
urgent interest | 2 |
prevent covid | 2 |
public security | 2 |
blue line | 2 |
time per | 2 |
three genotypes | 2 |
second largest | 2 |
insights regarding | 2 |
viral targets | 2 |
time horizon | 2 |
camp ashland | 2 |
another report | 2 |
hospitalized covid | 2 |
question regarding | 2 |
esquivel pineda | 2 |
intravenous immune | 2 |
viral particles | 2 |
countries using | 2 |
home isolation | 2 |
individual monotherapies | 2 |
noninvasive ventilation | 2 |
proportion meta | 2 |
critical illness | 2 |
mice used | 2 |
expert advice | 2 |
often asymptomatic | 2 |
attributes connecting | 2 |
associated comorbidity | 2 |
qualitative variables | 2 |
basic military | 2 |
among local | 2 |
prolonged qt | 2 |
commission nationale | 2 |
american african | 2 |
active components | 2 |
hiv testing | 2 |
infection spontaneous | 2 |
differs substantially | 2 |
potential extrapulmonary | 2 |
findings may | 2 |
science students | 2 |
students attended | 2 |
infection causing | 2 |
mice showed | 2 |
clinical severity | 2 |
participating students | 2 |
estimated million | 2 |
infection associated | 2 |
much higher | 2 |
dataset contains | 2 |
national level | 2 |
treatment may | 2 |
disease epidemic | 2 |
lung tissues | 2 |
summary statistics | 2 |
many patients | 2 |
biological activity | 2 |
flavonoids casticin | 2 |
highly efficient | 2 |
positive pressure | 2 |
pj fywwc | 2 |
broad spectrum | 2 |
epidemiological situation | 2 |
specific therapies | 2 |
proteinaceous debris | 2 |
pharmaceutical governance | 2 |
vulnerability stemming | 2 |
education system | 2 |
vaccine campaign | 2 |
global prevalence | 2 |
human ace | 2 |
pressure rooms | 2 |
outpatient visits | 2 |
seasonal influenza | 2 |
intravenous vancomycin | 2 |
critical preparedness | 2 |
higher levels | 2 |
essential oil | 2 |
wan wen | 2 |
significant reduction | 2 |
malaria infections | 2 |
patients provided | 2 |
epidemiological studies | 2 |
new covid | 2 |
year period | 2 |
arab emirates | 2 |
school environment | 2 |
antiviral clearance | 2 |
siglo xxi | 2 |
threatening products | 2 |
peripancreatic fat | 2 |
surveillance program | 2 |
participants experiencing | 2 |
ensure optimal | 2 |
term school | 2 |
radiological changes | 2 |
cutting funding | 2 |
bayesian methods | 2 |
following severe | 2 |
gated chlorine | 2 |
trials revealed | 2 |
first dose | 2 |
etiological agent | 2 |
data analysis | 2 |
th grade | 2 |
following weeks | 2 |
interim data | 2 |
also estimated | 2 |
cases continue | 2 |
plant extracts | 2 |
infections differs | 2 |
denv outbreaks | 2 |
quarantine facility | 2 |
policies aimed | 2 |
adequate sanitation | 2 |
advocate strongly | 2 |
posttest questionnaires | 2 |
nigerian centre | 2 |
regulatory functions | 2 |
national medical | 2 |
man presented | 2 |
dimie title | 2 |
data used | 2 |
thai national | 2 |
last days | 2 |
cases compared | 2 |
surinamese participants | 2 |
medical regulatory | 2 |
western kenya | 2 |
developing severe | 2 |
body temperature | 2 |
posterior predictions | 2 |
extrapulmonary virus | 2 |
interstitial involvement | 2 |
answered correctly | 2 |
taste disorders | 2 |
virus targeting | 2 |
monte carlo | 2 |
next days | 2 |
keeping rigor | 2 |
i error | 2 |
drug resistance | 2 |
urban settings | 2 |
wastewater treatment | 2 |
counterfeit medicines | 2 |
international pharmaceutical | 2 |
secondary denv | 2 |
biological samples | 2 |
provides key | 2 |
histopathology score | 2 |
personally prepared | 2 |
kong vm | 2 |
significant burden | 2 |
evaluation strategy | 2 |
preliminary results | 2 |
atypical presentations | 2 |
china molecular | 2 |
school holidays | 2 |
experiencing respiratory | 2 |
symptom status | 2 |
frontal lobe | 2 |
initial experience | 2 |
provided consent | 2 |
health governance | 2 |
internal medicine | 2 |
different origins | 2 |
oxygen supplementation | 2 |
medical countermeasure | 2 |
strongly agree | 2 |
denied recent | 2 |
samples collected | 2 |
vector control | 2 |
molecular diagnostic | 2 |
complicated epidemic | 2 |
nih clinical | 2 |
diagnostic approaches | 2 |
several clinical | 2 |
weeks later | 2 |
among immigrants | 2 |
genital primordium | 2 |
noninvasive positive | 2 |
based covid | 2 |
collection date | 2 |
dipeptidyl peptidase | 2 |
nln jn | 2 |
statistical computing | 2 |
one school | 2 |
continuous veno | 2 |
soft law | 2 |
key pathogens | 2 |
early stages | 2 |
characterize covid | 2 |
oral twice | 2 |
better treatment | 2 |
potential neuropathogenesis | 2 |
gut enterocytes | 2 |
multiple pathogens | 2 |
epidemic trend | 2 |
nacional siglo | 2 |
severe pulmonary | 2 |
vaccination programs | 2 |
ionizing radiation | 2 |
malaria parasite | 2 |
clinical information | 2 |
response office | 2 |
intravascular coagulation | 2 |
using adaptive | 2 |
among imported | 2 |
alveolar space | 2 |
potential health | 2 |
rsv detection | 2 |
resourcelimited settings | 2 |
open source | 2 |
collection day | 2 |
microthrombi may | 2 |
causes multiple | 2 |
potential utility | 2 |
patients died | 2 |
significantly younger | 2 |
clinical care | 2 |
develop severe | 2 |
pcr test | 2 |
inhibiting antibody | 2 |
models suggest | 2 |
chlorine channels | 2 |
presenting feature | 2 |
experimental studies | 2 |
initially negative | 2 |
surveillance platforms | 2 |
small sample | 2 |
differential diagnosis | 2 |
take necessary | 2 |
system described | 2 |
two royal | 2 |
fake covid | 2 |
neurological manifestation | 2 |
islamic scholars | 2 |
database search | 2 |
four schools | 2 |
significantly different | 2 |
human waste | 2 |
mtjk rp | 2 |
collect data | 2 |
limited viral | 2 |
falsified product | 2 |
multiple regions | 2 |
control policies | 2 |
resected bowel | 2 |
increase knowledge | 2 |
central irb | 2 |
qualitative study | 2 |
analysis reveals | 2 |
antibody titer | 2 |
care immunodiagnostic | 2 |
testing kits | 2 |
chest imaging | 2 |
chest ultrasound | 2 |
median incubation | 2 |
peripheral thrombosis | 2 |
included seven | 2 |
combination regimens | 2 |
related corruption | 2 |
university hospital | 2 |
presymptomatic infectorinfectee | 2 |
raising awareness | 2 |
affordable measures | 2 |
hour intervals | 2 |
underlying pathophysiology | 2 |
first confirmed | 2 |
negative serology | 2 |
care hospitals | 2 |
naive population | 2 |
microcirculatory function | 2 |
pattern detected | 2 |
inflammation associated | 2 |
hospitalization days | 2 |
antiviral agents | 2 |
hot spots | 2 |
via olfactory | 2 |
cov diseases | 2 |
respiratory manifestations | 2 |
surface antigen | 2 |
transmission characteristics | 2 |
denv protein | 2 |
improving global | 2 |
presented low | 2 |
african epidemic | 2 |
latent infection | 2 |
limited number | 2 |
chemokine mig | 2 |
mild cases | 2 |
molecular phylogeny | 2 |
showed leukocytosis | 2 |
reported case | 2 |
fifth day | 2 |
pneumonia requiring | 2 |
among travelers | 2 |
extrapulmonary features | 2 |
adaptive clinical | 2 |
breeding places | 2 |
sewage systems | 2 |
used routinely | 2 |
cerebral venous | 2 |
patients presented | 2 |
measures taken | 2 |
severe rhabdomyolysis | 2 |
address correspondence | 2 |
conducted among | 2 |
malaria endemicity | 2 |
immune globulin | 2 |